AbbVie (ABBV) Competitors $198.77 +2.47 (+1.26%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$199.50 +0.73 (+0.37%) As of 06:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABBV vs. AMGN, GILD, MRNA, ABT, BMY, JNJ, LLY, MRK, PFE, and ZTSShould you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), and Zoetis (ZTS). These companies are all part of the "medical" sector. AbbVie vs. Its Competitors Amgen Gilead Sciences Moderna Abbott Laboratories Bristol Myers Squibb Johnson & Johnson Eli Lilly and Company Merck & Co., Inc. Pfizer Zoetis Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings. Do analysts rate AMGN or ABBV? Amgen currently has a consensus target price of $303.76, suggesting a potential upside of 6.70%. AbbVie has a consensus target price of $214.43, suggesting a potential upside of 7.88%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 11 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.33AbbVie 0 Sell rating(s) 7 Hold rating(s) 17 Buy rating(s) 3 Strong Buy rating(s) 2.85 Does the media refer more to AMGN or ABBV? In the previous week, AbbVie had 28 more articles in the media than Amgen. MarketBeat recorded 129 mentions for AbbVie and 101 mentions for Amgen. Amgen's average media sentiment score of 1.13 beat AbbVie's score of 1.02 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 60 Very Positive mention(s) 8 Positive mention(s) 19 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive AbbVie 76 Very Positive mention(s) 18 Positive mention(s) 21 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Which has preferable earnings & valuation, AMGN or ABBV? AbbVie has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.58$4.09B$12.2323.28AbbVie$56.33B6.23$4.28B$2.1094.65 Is AMGN or ABBV more profitable? Amgen has a net margin of 18.96% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 699.66% beat Amgen's return on equity.Company Net Margins Return on Equity Return on Assets Amgen18.96% 174.71% 13.12% AbbVie 6.45%699.66%13.64% Which has more risk & volatility, AMGN or ABBV? Amgen has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Do institutionals and insiders believe in AMGN or ABBV? 76.5% of Amgen shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.8% of Amgen shares are held by insiders. Comparatively, 0.3% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is AMGN or ABBV a better dividend stock? Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.3%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 312.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and lower payout ratio. SummaryAbbVie beats Amgen on 13 of the 20 factors compared between the two stocks. Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABBV vs. The Competition Export to ExcelMetricAbbVieLarge Cap Pharma IndustryMedical SectorNYSE ExchangeMarket Cap$346.78B$239.00B$5.48B$20.71BDividend Yield3.34%3.02%3.99%3.67%P/E Ratio94.6529.1629.8928.65Price / Sales6.234.52421.4469.00Price / Cash13.1512.9335.9423.59Price / Book-2,484.597.978.124.32Net Income$4.28B$8.49B$3.26B$995.66M7 Day Performance1.84%-1.28%0.69%1.91%1 Month Performance4.83%-5.44%2.48%-0.54%1 Year Performance4.44%-11.26%27.93%14.76% AbbVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABBVAbbVie4.6681 of 5 stars$198.77+1.3%$214.43+7.9%+6.0%$346.78B$56.33B94.6555,000Trending NewsAnalyst UpgradeInsider TradeAMGNAmgen4.5861 of 5 stars$299.58+0.9%$307.27+2.6%-8.9%$161.07B$33.42B27.3328,000Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionGILDGilead Sciences4.66 of 5 stars$113.77+0.5%$112.36-1.2%+49.0%$141.57B$28.75B23.9617,600Trending NewsEarnings ReportMRNAModerna4.3276 of 5 stars$27.49-0.5%$46.11+67.8%-67.4%$10.61B$3.06B-3.645,800Trending NewsEarnings ReportAnalyst RevisionABTAbbott Laboratories4.9084 of 5 stars$129.30+1.6%$144.47+11.7%+20.1%$224.88B$41.95B16.19114,000Positive NewsBMYBristol Myers Squibb4.629 of 5 stars$45.13+2.0%$57.33+27.0%-2.5%$91.74B$48.30B18.1734,100Analyst DowngradeJNJJohnson & Johnson4.6829 of 5 stars$169.66+1.4%$174.50+2.9%+7.9%$408.40B$88.82B18.14138,100Positive NewsLLYEli Lilly and Company4.8944 of 5 stars$765.59+0.4%$1,012.56+32.3%-17.1%$723.84B$45.04B62.1447,000Trending NewsEarnings ReportAnalyst ForecastGap DownMRKMerck & Co., Inc.4.9934 of 5 stars$79.46+0.2%$107.44+35.2%-28.6%$199.42B$64.17B12.2475,000Positive NewsPFEPfizer4.9867 of 5 stars$23.61+0.5%$28.28+19.8%-15.9%$134.20B$63.63B17.1181,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionZTSZoetis4.8038 of 5 stars$151.59+2.9%$204.63+35.0%-19.9%$67.44B$9.29B27.1913,800Trending NewsEarnings ReportAnalyst Revision Related Companies and Tools Related Companies AMGN Competitors GILD Competitors MRNA Competitors ABT Competitors BMY Competitors JNJ Competitors LLY Competitors MRK Competitors PFE Competitors ZTS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABBV) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.